

1 **Longitudinal profiles of dietary and microbial metabolites in formula-**
2 **and breastfed infants**

3 Nina Sillner^{1,2}, Alesia Walker^{1*}, Marianna Lucio¹, Tanja V Maier¹, Monika Bazanella³,
4 Michael Rychlik⁴, Dirk Haller^{2,3}, Philippe Schmitt-Kopplin^{1,2,4}

5 ¹Research Unit Analytical BioGeoChemistry, Helmholtz Zentrum München, Neuherberg,
6 Germany

7 ²ZIEL Institute for Food and Health, Technical University of Munich, Freising, Germany

8 ³Chair of Nutrition and Immunology, Technical University of Munich, Freising, Germany

9 ⁴Chair of Analytical Food Chemistry, Technical University of Munich, Freising, Germany

10 *Corresponding author

11

12

13 **ABSTRACT**

14 The early-life metabolome of the intestinal tract is dynamically influenced by colonization
15 of gut microbiota which in turn is affected by nutrition, i.e. breast milk or formula. A detailed
16 examination of fecal metabolites was performed to investigate the effect of probiotics in
17 formula compared to control formula and breast milk within the first months of life in
18 healthy neonates. A broad metabolomics approach was conceptualized to describe fecal
19 polar and semi-polar metabolites affected by diet within the first year of life. Fecal
20 metabolomes were clearly distinct between formula- and breastfed infants, mainly
21 originating from diet and microbial metabolism. Unsaturated fatty acids and human milk
22 oligosaccharides were increased in breastfed, whereas Maillard products were found in
23 feces of formula-fed children. Altered microbial metabolism was represented by bile acids
24 and aromatic amino acid metabolites. Elevated levels of sulfated bile acids were detected
25 in stool samples of breastfed infants, whereas secondary bile acids were increased in
26 formula-fed infants. Co-microbial metabolism was supported by significant correlation
27 between chenodeoxycholic or lithocholic acid and members of Clostridia. Fecal
28 metabolites showed strong inter- and intra-individual behavior with features uniquely
29 present in certain infants and at specific time points. Nevertheless, metabolite profiles
30 converged at the end of the first year, coincided with solid food introduction.

31

32 **Keywords:** infant; feces; metabolomics; infant formula; bifidobacteria; probiotics;
33 formula-fed; breastfed

34 INTRODUCTION

35 Nutrition during the early postnatal life is an important factor that might influence health
36 throughout the whole life (Robinson 2015). Breastmilk is the recommended feeding during
37 the first six months, as pointed out by world health organization (WHO n.d.). From a
38 nutritional point of view breastmilk contains an appropriate composition of macronutrients
39 and micronutrients, important for the child's development. Macronutrients include
40 carbohydrates (lactose, oligosaccharides), fat (triglycerides with saturated and
41 polyunsaturated fatty acids) and proteins (casein or whey proteins such as α -lactalbumin,
42 lactoferrin, secretory IgA, and serum albumin) (Prentice 1996). There is a substantial
43 variation of breastmilk components between mothers depending on diet and age. Infant
44 formula is an industrially produced alternative to breast milk and is used either as a sole
45 food source or to complement breast milk in early life. Infant formulas are based on cow
46 milk, soy or meet special requirements such as hypoallergenic formulas (Koletzko, Baker
47 et al. 2005, Martin, Ling et al. 2016). Feeding of infants with breastmilk or formula is
48 discussed to contribute to different outcomes in health and disease and is a focus in
49 various research fields such as gut microbiome or metabolomics.

50 A non-targeted metabolomics approach using LC-MS based techniques can be utilized
51 to study diet-related differences between breast- and formula-fed infants. Urine or fecal
52 samples are considered as non-invasive matrices to profile metabolites in health-disease
53 related issues (Wild, Shanmuganathan et al. 2019). Complementary to the gut
54 microbiome research, stool metabolites can reflect changes in gut microbial metabolism.
55 Additionally, excreted host derived metabolites or digested food ingredients provide
56 insights into non-microbial metabolism. In previous work, we are able to show that the

57 fecal metabolome and gut microbiome is altered between breast- and formula-fed infant
58 in the first year of life with converging profiles at the age of 12 months. Probiotic
59 supplementation with bifidobacteria showed only minor effects on both, fecal microbiome
60 and metabolome. Despite the identification of short chain fatty acids, only a shallow
61 description of metabolites was given, with few mass signals and the respective annotated
62 classes (Bazanella, Maier et al. 2017). Here, we extend our non-targeted metabolomics
63 approach by combining different chromatographic approaches to analyze polar and semi-
64 polar metabolites in infant stool and formula or breastmilk, and supporting our metabolite
65 identities with MS based fragmentation experiments and authentic standard matching.
66 The detailed examination between breast- and formula-fed infants allowed us to
67 discriminate between nutrition or microbe derived alterations in the fecal metabolome.
68 Metabolite profiles were monitored at several time points during the first year of life,
69 including a follow-up study one year later, enabling a longitudinal comparison of infant
70 diets.

71 MATERIALS AND METHODS

72 **Study design.** Stool samples (n = 244, Table S1) from healthy infants, who received
73 infant formula with (n = 11, F+), without (n = 11, F-) bifidobacteria (*B. bifidum*, *B. breve*,
74 *B. infantis*, *B. longum*) or exclusively breast milk (n = 20, B) were collected over a period
75 of two years in a randomized, double-blinded, placebo-controlled intervention trial as
76 described elsewhere (Bazanella, Maier et al. 2017). Fecal samples of month 1, 3, 5, 7, 9,
77 12 and 24 were selected for non-targeted analysis. Additionally, breast milk samples (n =
78 36) were collected at different time points and categorized in samples from secretor (n =
79 30) and non-secretor mothers (n = 6) (Bazanella, Maier et al. 2017). Furthermore, mother-
80 child and time matching infant fecal samples (n = 31) were selected for comparison of
81 HMO levels between breast milk and associated infant feces. The trial was registered at
82 the German Clinical Trials Register (DRKS00003660) and the protocol was approved by
83 the ethics committee of the medical faculty of the Technical University of Munich
84 (approval number 5324/12).

85 **Chemicals.** Arachidonic acid, eicosapentaenoic acid, myristic acid, 4-
86 hydroxyphenyllactic acid, indolelactic acid, phenyllactic acid, 6'-sialyllactose,
87 chenodeoxycholic acid (CDCA), cholic acid (CA), ursodeoxycholic acid (UDCA),
88 lithocholic acid (LCA), glychochenodeoxycholic acid (GCDCA) and
89 taurochenodeoxycholic acid (TCDCA) were purchased from Sigma-Aldrich (St. Louis,
90 USA). 7-oxoLCA, 3-dehydroCDCA, 7,12-dioxoLCA, 7-oxodeoxycholic acid (7-oxoDCA),
91 3-dehydroCA, 7-epiCA, glycocholic acid (GCA) and taurocholic acid (TCA) were
92 purchased from Steraloids (Newport, RI, USA). Cholic acid 7-sulfate (CA-S) and 3'-

93 sialyllactose were purchased from Cayman (Biomol GmbH, Hamburg, Germany). Sulfate
94 (S) conjugates of CDCA, UDCA and LCA were synthesized according to Donazzolo et al.
95 (Donazzolo, Gucciardi et al. 2017) and structures were verified by MS/MS and NMR
96 spectroscopy (data not shown). Milli-Q water (18.2 M Ω) was derived from a Milli-Q
97 Integral Water Purification System (Billerica, MA, USA). Acetonitrile (ACN; LiChrosolv®,
98 hypergrade for LC-MS), methanol (LiChrosolv®, hypergrade for LC-MS) and ammonium
99 acetate (NH₄Ac) were obtained from Merck (Darmstadt, Germany). Glacial acetic acid
100 was purchased from Biosolve (Valkenswaard, Netherlands) and formic acid from
101 Honeywell Fluka™ (Morristown, NJ, USA).

102 **Fecal sample preparation.** Metabolite extraction from infant stool samples was prepared
103 with methanol as described previously (Bazanella, Maier et al. 2017). For hydrophilic
104 interaction liquid chromatography (HILIC) analysis the methanol extracts were
105 evaporated under vacuum at 40 °C (SpeedVac Concentrator, Savant SPD121P,
106 ThermoFisher Scientific, Waltham, MA, USA) and reconstituted with ACN/H₂O 75:25
107 (v/v). A pooled sample was generated from all fecal extracts for quality control purpose.
108 All samples were stored at -80 °C in tightly closed tubes.

109 **Breast milk sample preparation.** For HILIC measurements, 125 μ L breast milk was
110 extracted with 375 μ L acetonitrile. The mixture was vortexed, centrifuged with 14,000 rpm
111 at 4 °C for 10 min and the supernatant was collected. A pooled sample was generated
112 from all breast milk extracts for quality control purpose. All samples were stored at -80 °C
113 in tightly closed tubes.

114 **Quantification of fatty acids in formula and breast milk.** Breast milk samples from
115 lactation month 1 (n = 26), month 3 (n = 28) and month 4 (n = 9) were pooled, respectively.
116 Additionally, 3 types of infant formula (pre, 1 and 2), consumed by infants of this study,
117 were mixed with hot tap water (~50 °C) according to manufacturer instructions. The
118 method for quantification of the fatty acids in the different milk samples was described by
119 Firl et al. (Firl, Kienberger et al. 2014).

120 **UHPLC-MS/MS screening.** The fecal and milk extracts and standard substances (in
121 ACN/H₂O 75:25, v/v for HILIC or methanol for RP) were analyzed by UHPLC (Acquity,
122 Waters, Milford, MA, USA) coupled to a time of flight (TOF) mass spectrometer (MS)
123 (maXis, Bruker Daltonics, Bremen, Germany). HILIC was performed using an iHILIC®-
124 Fusion UHPLC column SS (100x2.1 mm, 1.8 µm, 100 Å, HILICON AB, Umea, Sweden).
125 Chromatographic settings were the same as previously described (Sillner, Walker et al.
126 2019) with the following modifications: injection volume was 5 µL, eluent A consisted of
127 5 mmol/L NH₄Ac (pH 4.6) in 95% ACN (pH 4.6) and eluent B of 25 mmol/L NH₄Ac (pH
128 4.6) in 30% ACN with a runtime of 12.1 min, followed by reconditioning for 5 min after
129 each sample, respectively. Every tenth injection a pooled fecal sample was used as
130 quality control for subsequent batch normalization.

131 Calibration of the MS was done by injecting ESI-L Low Concentration Tuning Mix (Agilent,
132 Santa Clara, CA, USA) prior to the measurements. Additionally, ESI-L Low Concentration
133 Tuning Mix (diluted 1:4 (v/v) with 75% ACN) was injected in the first 0.3 min of each
134 UHPLC-MS/MS run by a switching valve for internal recalibration. Mass spectra were
135 acquired in negative electrospray ionization mode (-ESI), respectively. Parameters of the
136 ESI source were: nitrogen flow rate: 10 L/min, dry heater: 200 °C, nebulizer pressure: 2

137 bar and capillary voltage: 4000 V. Data were acquired in line and profile mode with an
138 acquisition rate of 5 Hz within a mass range of 50–1500 Da. Data-dependent MS/MS
139 experiments were performed in automated MS/MS mode. After each precursor scan, the
140 five most abundant ions (absolute intensity threshold ≥ 2000 arbitrary units) were
141 subjected to MS/MS. Each fecal sample was measured in duplicates with a collision
142 energy of 10 and 35 eV, respectively. The RP UHPLC-MS measurements for non-
143 targeted metabolomics and short chain fatty acid analysis are described elsewhere
144 (Bazanella, Maier et al. 2017).

145 Raw UHPLC-MS data were processed with Genedata Expressionist Refiner MS 11.0
146 (Genedata GmbH, Munich, Germany), including chemical noise subtraction, intensity cut-
147 off filter, calibration, chromatographic peak picking and deisotoping. Metabolite library
148 search and classification was done with the Human Metabolome Database (HMDB)
149 (Wishart, Feunang et al. 2018) for MS1 or MS2 spectra (± 0.005 Da). Manual classification
150 was done for Maillard reaction products.

151 Peak areas of duplicates were averaged and normalized to fecal weight. Batch
152 normalization based on consecutive quality control measurement samples (pooled
153 sample) was performed after missing value imputation (randomized number between 1.0
154 and 1.2, based on lowest value of the data matrix).

155 Targeted MS/MS experiments of Amadori products were performed in multiple reaction
156 monitoring mode (MRM) at 20 eV in positive ionization mode (Sillner, Walker et al. 2019).

157 **Statistical analysis.** Multilevel partial least squares discriminant analysis (PLS-DA) was
158 applied to consider the paired and multi-factorial (diet and time) design of the study. The
159 validity of the multilevel PLS-DA model was confirmed by 7-fold cross validation and
160 receiver operating characteristic (ROC) curves, by evaluating the first and second
161 component. Regularized canonical correlation analysis (rCCA) was applied for correlation
162 between OTU (operational taxonomic unit) and bile acid data (Meng, Kuster et al. 2014).
163 The vertical integration method combined the two datasets (Sperisen, Cominetti et al.
164 2015). Inter- and intra-individual metabolites were selected by multiple co-inertia analysis,
165 available at the omicade4 package of R environment (Meng, Kuster et al. 2014). Prior all
166 analyses, data was log-transformed and unit-variance scaled.

167 **High-throughput 16S rRNA gene sequencing.** Samples were prepared and analyzed
168 as described previously (Bazanella, Maier et al. 2017).

169

170 **RESULTS AND DISCUSSION**

171 **Time independent feeding effects on the fecal metabolome**

172 The particular design of the infant study with longitudinal sampling requires appropriate
173 statistical methods due to high dimensional and co-linear metabolite data. By applying a
174 multilevel PLS-DA analysis, the time dependent effects in this study were eliminated and
175 metabolites representing the effects of the different feeding types, i.e. breastfed (B, blue)
176 or formula-fed (F-/ F+, orange or green) were extracted (Fig. 1). The first component of
177 the multilevel PLS-DA explained 4% (HILIC, Fig. 1A) and 3% (RP, Fig. 1B) of the total
178 variance between B and F groups. Despite the clear visual separation of feeding groups,
179 the relatively low percentage of the feeding variable on the total variance can be explained
180 by the fact that infant fecal metabolomes are influenced by many different variables such
181 as the amount of food, gastrointestinal passage or digestion status and sampling time, all
182 contributing to the variability. Probiotic treatment (F+, green) could explain only 1% of the
183 total variance in the metabolite data. Only few infants of the F+ group in month 1 and 3
184 seems to respond to probiotics, as seen in the right lower corner of Fig 1A and B. Receiver
185 Operator Characteristic (ROC) curves of the multilevel PLS-DA component 1 confirmed
186 with around 0.99 classification accuracy that B are highly distinct from F groups (Fig. S1,
187 A, C). Probiotic supplemented vs. non-supplemented formula feeding, represented in
188 component 2 (Fig. 1), resulted in slightly lower classification accuracy of around 0.98 (Fig.
189 S1, B, D). For further investigations, the most contributing features (top 15%) were
190 selected from the loadings plot, starting from lowest (B) or highest (F- and F+) principle
191 component 1 (p1) coordinates and the same for principle component 2 (p2) coordinates
192 (F- vs. F+) values (Fig. 1C, D).

193 Putative annotation of features indicated that group B is described by “*fatty acids and*
194 *conjugates*” for RP and “*carbohydrates and carbohydrate conjugates*” for HILIC analysis,
195 whereas many characteristic metabolites of both F groups turned out to be Maillard
196 reaction derived compounds, especially Amadori products (Sillner, Walker et al. 2019).
197 During the identification process, features were grouped either in nutrition or microbe
198 derived metabolites, based on existing literature (Bode 2012, Pischetsrieder and Henle
199 2012, Dodd, Spitzer et al. 2017, Sillner, Walker et al. 2018, Pranger, Corpeleijn et al.
200 2019). Metabolites were annotated (level 3) or identified (level 1 and 2). The list of all
201 features of the RP and HILIC analysis including the loadings information is available in
202 Tab. S1.

203

204 **Nutrition derived metabolites in course of time**

205 **Increased fatty acids in breastfed children reflected fatty acid composition of** 206 **breastmilk**

207 The semi-polar fecal metabolome of group B was discriminated by the subclass of fatty
208 acids and conjugates. In feces of breastfed infants the saturated fatty acid myristic acid
209 (C14:0) was elevated from month (m) 1 – 5. In formula-fed infants myristic acid was very
210 low abundant during the first 3 months, but showed very similar levels to breastfed infants
211 at month 12 and 24 (Fig. 2A), probably due to the predominant solid food nutrition in all
212 of the groups at this age. Myristic acid was also reported to be higher in cecal contents of
213 breast-fed piglets (Poroyko, Morowitz et al. 2011). On the contrary, a different study
214 reported myristic acid to be significantly higher in formula-fed infants (Chow, Panasevich
215 et al. 2014), which could be due to the variable fatty acid composition of different infant

216 formulas. To verify our findings we quantified the fatty acids in breast milk and infant
217 formula relevant for our study (Tab. S2). Indeed, the average concentration of myristic
218 acid in breast milk was found to be much higher than in the infant formulas (pre, 1, 2)
219 consumed by our cohort. Furthermore, also the long chain poly-unsaturated fatty acids
220 arachidonic (Fig. 2B) and eicosapentaenoic acid (Fig. 2C) were increased in breastfed
221 infants compared to the two formula-fed groups up to month 7. Again, this relation was
222 confirmed in the fatty acid analysis of breast milk and formula (Tab. S2), showing higher
223 concentrations of arachidonic and eicosapentaenoic acid in breast milk. Although, the
224 total amount of poly-unsaturated fatty acids was higher in formula.

225

226 **Infant fecal HMOs reflected the secretor status of the mothers**

227 In the HILIC analysis, human milk oligosaccharides (HMOs) were very characteristic for
228 the fecal metabolome of breastfed infants. HMOs are only present in human breast milk,
229 therefore these mass signals were absent in the formula-fed group. The HMO profile in
230 breast milk is determined by the secretor status. Non-secretor mothers have an inactive
231 allele of the maternal fucosyltransferase 2 (FUT2) gene and therefore can't produce α 1-
232 2 fucosylated HMOs, e.g. 2'-fucosyllactose. According to this, breast milk samples were
233 classified in secretor (n = 30) and non-secretor (n = 6) samples by Bazanella et al.
234 (Bazanella, Maier et al. 2017). This classification was also done for mother-child matched
235 fecal samples to examine the influence of the mothers secretor status on the HMO profiles
236 in feces of their infants by applying a non-targeted profiling HILIC-MS approach (Sillner,
237 Walker et al. 2019) on both matrices. In total, we detected 6 HMOs (Fig. 3). Unfortunately,
238 no differentiation between 2'-fucosyllactose and 3'-fucosyllactose was possible with the

239 non-targeted screening method, therefore both were summarized as fucosyllactose. The
240 relation of the HMOs in breast milk from secretor vs. non-secretors were very precisely
241 reflected in the fecal samples of infants from the corresponding secretor vs. non-secretor
242 mothers (Fig. 3). Interestingly, this was not only the case for fucosylated but also for
243 sialylated HMOs, like 3'- and 6'-sialyllactose. This illustrates that the mothers secretor
244 status can also be determined by analyzing HMOs in infant stool. The secretor status also
245 influences the infant gut microbiota composition. Feeding with breast milk from secretor
246 mothers enhances the colonization with specific bifidobacteria, which are common infant
247 gut commensals (Lewis, Totten et al. 2015, Bazanella, Maier et al. 2017).

248

249 **Maillard reaction products dominated the stool metabolome of formula-fed infants**

250 Recently, we identified the milk-derived Amadori products *N*-deoxylactulosyl- and *N*-
251 deoxyfructosyllysine and *N*-deoxylactulosyl- and *N*-deoxyfructosylleucylisoleucine in
252 stool from the same cohort, which were only present in formula-fed infants (Sillner, Walker
253 et al. 2019). Amadori products are early Maillard reaction products and are formed during
254 infant formula production, mainly between lactose and protein bound amino acids (*N*-
255 terminal or lysine side chains). We were able to annotate further Amadori products as
256 significant features of metabolome the formula-fed children, due to their characteristic
257 MS/MS patterns (Fig. 4). The *m/z* signal 381.1338 was only present in formula-fed infants
258 and decreased slowly with time, most likely due to solid food introduction (Fig. 4A, Tab.
259 S1). MRM fragmentation in positive mode of the corresponding *m/z* signal 383.1481 is
260 shown in Fig. 4B. Dominant fragment ions were neutral losses of water, loss of 84 Da (-
261 3H₂O-CH₂O) and loss of the glucose moiety (162 Da), which are characteristic for the

262 Amadori compound class (Hegele, Buetler et al. 2008, Wang, Lu et al. 2008, Ruan 2018,
263 Sillner, Walker et al. 2019). Accordingly, this metabolite was annotated as *N*-
264 deoxyfructosylmethionylalanine (FruMetAla) due to its exact mass (± 0.005 Da mass
265 tolerance), MS/MS fragmentation pattern and the matching N-terminal amino acid
266 sequence MetAla of the formula ingredient glycomacropeptide (Neelima, Sharma et al.
267 2013). Glycomacropeptide is released from κ -casein during whey powder production and
268 remains in the sweet whey fraction, which is among others used for infant formula (Rigo,
269 Boehm et al. 2001). Furthermore, two peaks were annotated as *N*-
270 deoxyfructosylacetyllysine (FruAcLys) (Fig. S2). Their fragmentation patterns are similar,
271 however the earlier eluting peak (6.2 min) exhibits the typical loss for Amadori products
272 of 84 Da (Fig. S2A), whereas the peak at 6.6 min shares also fragments with *N*-
273 deoxyfructosyllysine (FruLys) (Fig. S2B) (Sillner, Walker et al. 2019). During the Maillard
274 reaction 1-deoxy-2,3-hexodiulose reacts with lysine and degrades to acetyllysine via β -
275 dicarbonyl cleavage (Smuda, Voigt et al. 2010, Henning, Smuda et al. 2011). Since lysine
276 has two amine groups, formation of an acetyllysine Amadori product could be possible
277 during infant formula production. Indeed, we were able to detect peaks with the same
278 mass and retention time in a model reaction mixture of L-lysine with glucose heated for 1
279 h at 100 °C in water, maybe deriving from glycated α - and ϵ -acetyllysine (Fig. S2C).
280 FruAcLys and especially FruMetAla could serve as specific nutrition markers for formula-
281 fed infants, similar to the previously proposed *N*-deoxyfructosyl-/ *N*-
282 deoxylactulosylleucylisoleucine (Sillner, Walker et al. 2019).

283 **Microbial derived metabolites in course of time**

284 **Diet and time dependent alteration of microbial aromatic amino acid metabolites**

285 During the first year, 4-hydroxyphenyllactic and indolelactic acid (Fig. 5A, B) were
286 increased in fecal samples of breastfed infants. Although 4-hydroxyphenyllactic and
287 indolelactic acid were not significantly changed between F- and F+, higher intensity levels
288 were observed for the bifidobacteria-supplemented F+ group at month 3 and 5. It was
289 reported that bifidobacteria, which are predominant gut microbes in breastfed children,
290 produce phenyllactic, 4-hydroxyphenyllactic (Beloborodova, Khodakova et al. 2009,
291 Beloborodova, Bairamov et al. 2012) and indolelactic acid (Aragozzini, Ferrari et al. 1979)
292 from the aromatic amino acids phenylalanine, tyrosine and tryptophan, respectively.
293 However, the profiles of the corresponding amino acids didn't show any coherent
294 behavior in feces (Fig. S3), probably due to fluxes into multiple metabolite pathways.
295 Interestingly, phenyllactic acid showed a very different profile compared to the others with
296 no significant differences between the feeding groups but increasing levels over time (Fig.
297 5C). This may indicate that other bacterial species are settling the children's gut in the
298 course of time, which are able to produce higher amounts of phenyllactic acid. Whereas,
299 4-hydroxyphenyllactic and indolelactic acid almost disappeared completely during solely
300 solid food nutrition (24m).

301

302 **Formula feeding increased the variety of microbial secondary bile acids**

303 Furthermore, several bile acids were significantly affected by the different feeding types.
304 All detected bile acids and the bile acid precursor cyprinol sulfate (cyprinol-S) are
305 displayed in dependence of feeding and age in Fig. 6. Interestingly, the common

306 secondary bile acid LCA was almost absent until month 12. It was already described that
307 the concentration of secondary bile acids are much lower in children compared to adults
308 (Huang, Rodriguez et al. 1976) and that LCA producing bacteria (7 α -dehydroxylation) are
309 at first established in the gut at the age of 12 – 18 months (Eyssen 1973). Hammons et
310 al. were able to detect LCA in some infants already at the age of approximately 3 months
311 but with a high inter-individual variation (Hammons, Jordan et al. 1988).
312 Instead, other secondary bile acids were detected in the earlier months, namely 7-
313 oxoLCA, 3-dehydroCDCA, UDCA, 7-12-dioxoLCA, 7-oxoDCA, 3-dehydroCA and 7-
314 epiCA. Lester et al. already reported in the past about the presence of “unconventional”
315 bile acids in infant feces, like UDCA (Lester, St Pyrek et al. 1983). However, 7-oxoLCA,
316 3-dehydroCDCA, UDCA and 7-epiCA were higher in the formula-fed groups (F+ and F-).
317 This could be due to the fact, that formula-fed children showed a higher bacterial richness
318 and diversity compared to breastfed (B) (Bazanella, Maier et al. 2017). A higher excretion
319 of secondary bile acids in formula- compared to breastfed infants was also reported by
320 Hammons et al. (Hammons, Jordan et al. 1988). Group B, however, was strongly
321 characterized by sulfated bile acids during the first year. Sulfation of bile acids is a major
322 detoxification pathway in humans, which increases their solubility, decreases intestinal
323 absorption, and enhances fecal and urinary excretion. In human adults, it was reported
324 that more than 70% of bile acids in urine are sulfated, whereas the amount in feces is
325 much lower (Alnouti 2009). The high amount of sulfated bile acids in feces of breastfed
326 infants could be due to a defense mechanism against bile acid accumulation, which is
327 suggested in cholestatic diseases (Alnouti 2009), and a decreased absorption rate in the

328 large intestine compared to adults. Heubi et al. reported normal enterohepatic circulation
329 of bile acids to begin at first at the age of 3 – 7 months (Heubi, Balistreri et al. 1982).
330 The conjugated primary bile acids GCA and GCDCA were increased in F- during month
331 1 and 3. Bifidobacteria show bile salt hydrolase (BSH) activity and are able to deconjugate
332 bile acids (Grill, Manginot-Dürr et al. 1995, Tanaka, Hashiba et al. 2000, Kim, Miyamoto
333 et al. 2004, Begley, Hill et al. 2006, Degirolamo, Rainaldi et al. 2014). The intensities of
334 GCA and GCDCA in the probiotic F+ group during month 1 and 3 were lower and more
335 similar to group B, which could be a sign of probiotic activity.
336 Regularized canonical correlation analysis (rCCA) (González, Déjean et al. 2008,
337 González, Cao et al. 2012) was performed to explore relationships between bile acids
338 and OTU data (Fig. 7A). A representation of variables defined by the first two canonical
339 variates is displayed in Fig. S4. On the basis of the clustered image map of the cross-
340 correlation matrix (Fig. 7B) and relevance networks were generated (Fig. 7C).
341 Correlations between OTUs and bile acids with a strength $> \pm 0.3$ were found for CDCA,
342 LCA and 3-dehydroCDCA. Correlation strengths $> \pm 0.5$ were only calculated for CDCA
343 and LCA (Fig. 7B). Solely positive correlations were found within these limits. Most of the
344 correlating OTUs belong to the families *Lachnospiraceae* and *Ruminococcaceae*, both of
345 them belong to the class of Clostridia. It is known that many Clostridia species are able
346 to produce the secondary bile acid LCA from the primary bile acid CDCA via 7 α -
347 dehydroxylation. The secondary bile acid 3-dehydroCDCA is also produced from CDCA
348 but via 3 α -hydroxysteroid dehydrogenases, which were detected in Firmicutes (Fiorucci
349 and Distrutti 2015).

350

351 **Distinct time and diet inter-and intra-individual metabolite profiles**

352 Longitudinal studies in microbiome research often described highly inter- and intra-
353 individual variability (Zhou, Sailani et al. 2019). The metabolite profiling of stool samples
354 over time enables to determine the variability of each individual and metabolites that are
355 responsible for this behavior. The inter- and intra-individual behavior of the children was
356 elaborated by a multiple co-inertia analysis for the polar metabolome (Fig. 8) (Meng,
357 Kuster et al. 2014). For the exclusively breastfed group (B) only months 1 – 9 were taken
358 into account because of a reduced number of available samples in later months due to
359 weaning. In the breastfed group (Fig. 8A, Tab. S3), especially infant 66 showed very
360 individual profiles at certain time points. Metabolites responsible for this behavior were
361 for example 3-hydroxyphenylacetic acid in month 5, taurocholic acid in month 7 (Fig. S6A)
362 and N-acetylneuraminic acid in month 9. Infant 126 and 115 were characterized by
363 fucosyllactose in month 3 and ferulic acid sulfate in month 7.

364 In the F- group (Fig. 8B, Tab. S3) the individuality was less distinct. For infant 71
365 hydroxydecanoic acid (Fig. S6B) and polyphenolic compounds can be found in month 9
366 and 12, respectively. The individual profile of infant 30 is characterized e.g. by
367 pantothenol in month 3, which is often used in care products, and fucose in month 9.

368 In the F+ group (Fig. 8C, Tab. S3) infant 43 showed a different behavior over time due to
369 e.g. cyclamic acid (Fig. S6C), an artificial sweetener in month 3 and 3-
370 hydroxyphenylacetic acid in month 9, whereas infant 25 and 102 were characterized by
371 cyclamic acid in month 12 and 3-(4-hydroxyphenyl)-propionic acid in month 24.

372 The more differentiated positions of the metabolites in the loading plot of group B and F+
373 (Fig. S5A, C) compared to the F- group (Fig. S5B) indicates a more pronounced

374 individuality in group B and F+. For group B this could be explained by the fact that breast
375 milk composition can be quite variable between mothers and over lactation periods
376 (Villaseñor, Garcia-Perez et al. 2014, Hascoët, Chauvin et al. 2019, Hewelt-Belka,
377 Garwolińska et al. 2019, John, Sun et al. 2019), whereas the formula-fed infants always
378 received the same type of formula during the trial. Besides xenobiotics like cyclamic acid,
379 the individual behavior of the F+ group seemed to be more influenced by microbial
380 metabolites. Wandro et al. reported that the inter-individual effect on the metabolome of
381 infants over the first 6 weeks of life was stronger than any trends in clinical factors.
382 Furthermore, for some individual infants strong shifts in the metabolite profiles were
383 observed over time, while others remained more stable (Wandro, Osborne et al. 2018).
384 Not only the whole metabolome showed high intra- and inter-individual variability but also
385 specific metabolite classes such short chain fatty acids (McOrist, Miller et al. 2011). Infant
386 88 (B, Fig. 8D), 75 (F-, Fig. 8E) and 25 (F+, Fig. 8F) showed highest inter- and intra-
387 individual behavior of SCFAs. High dispersion of lactic acid over time was observed in
388 the loading plot of B group (Figure S7, A), but also for F- and F+ infants (Figure S7, B-C).
389 Butyric and propionic acid were also highly distributed over different time points in F- an
390 F+ infants. Valeric, isovaleric and pyruvic showed a more closed distribution for all feeding
391 groups.

392 In summary, the fecal metabolite profiles of the infant cohort was largely composed of
393 ingredients of consumed food and microbial metabolism of food compounds or co-
394 microbial metabolism of host derived metabolites (Fig. 9). Some of them are recovered
395 directly without modification in stool such as long chain fatty acids or HMOs and may be
396 directly linked to the child's or mother's diet or genotype. Furthermore, digested products
397 of food processing (glycated proteins) were found especially in feces of formula-fed
398 infants.

399 Altered microbial modification of amino acids or bile acids in breastfed and formula-fed
400 infants resulted in distinct metabolite profiles, hinting towards different gut microbial
401 populations and thus different microbial metabolism. It may reflect rather specialized or
402 absent microbial metabolism for example of aromatic amino acids through bifidobacteria
403 or increased sulfation of bile acids in breastfed children, respectively. Diverse microbial
404 metabolism was illustrated by several secondary bile acids in formula-fed children.
405 Overall, each individual was reflected by his own fecal metabolite profile and particular
406 metabolites displayed high inter- and individual variability, induced by different genetic
407 backgrounds or external influences, like the individual composition of breastmilk, the
408 amount of consumed formula or living environment.

409

410

411

412 REFERENCES

- 413 Alnouti, Y. (2009). "Bile Acid Sulfation: A Pathway of Bile Acid Elimination and
414 Detoxification." Toxicological Sciences **108**(2): 225-246.
- 415 Aragozzini, F., A. Ferrari, N. Pacini and R. Gualandris (1979). "Indole-3-lactic acid as a
416 tryptophan metabolite produced by *Bifidobacterium* spp." Applied and Environmental
417 Microbiology **38**(3): 544-546.
- 418 Bazanella, M., T. V. Maier, T. Clavel, I. Lagkouvardos, M. Lucio, M. X. Maldonado-Gomez, C.
419 Autran, J. Walter, L. Bode, P. Schmitt-Kopplin and D. Haller (2017). "Randomized controlled
420 trial on the impact of early-life intervention with bifidobacteria on the healthy infant fecal
421 microbiota and metabolome." Am J Clin Nutr **106**(5): 1274-1286.
- 422 Begley, M., C. Hill and C. G. M. Gahan (2006). "Bile Salt Hydrolase Activity in Probiotics."
423 Applied and Environmental Microbiology **72**(3): 1729-1738.
- 424 Beloborodova, N., I. Bairamov, A. Olenin, V. Shubina, V. Teplova and N. Fedotcheva (2012).
425 "Effect of phenolic acids of microbial origin on production of reactive oxygen species in
426 mitochondria and neutrophils." Journal of Biomedical Science **19**(1): 89.
- 427 Beloborodova, N. V., A. S. Khodakova, I. T. Bairamov and A. Y. Olenin (2009). "Microbial
428 origin of phenylcarboxylic acids in the human body." Biochemistry (Moscow) **74**(12): 1350-
429 1355.
- 430 Bode, L. (2012). "Human milk oligosaccharides: every baby needs a sugar mama." Glycobiology
431 **22**(9): 1147-1162.
- 432 Chow, J., M. R. Panasevich, D. Alexander, B. M. Vester Boler, M. C. Rossoni Serao, T. A.
433 Faber, L. L. Bauer and G. C. Fahey (2014). "Fecal Metabolomics of Healthy Breast-Fed versus
434 Formula-Fed Infants before and during In Vitro Batch Culture Fermentation." Journal of
435 Proteome Research **13**(5): 2534-2542.
- 436 Degirolamo, C., S. Rainaldi, F. Bovenga, S. Murzilli and A. Moschetta (2014). "Microbiota
437 modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-
438 Fgf15 axis in mice." Cell Rep **7**(1): 12-18.
- 439 Dodd, D., M. H. Spitzer, W. Van Treuren, B. D. Merrill, A. J. Hryckowian, S. K. Higginbottom,
440 A. Le, T. M. Cowan, G. P. Nolan, M. A. Fischbach and J. L. Sonnenburg (2017). "A gut
441 bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites." Nature
442 **551**(7682): 648-652.
- 443 Donazzolo, E., A. Gucciardi, D. Mazzier, C. Peggion, P. Pirillo, M. Naturale, A. Moretto and G.
444 Giordano (2017). "Improved synthesis of glycine, taurine and sulfate conjugated bile acids as
445 reference compounds and internal standards for ESI-MS/MS urinary profiling of inborn errors of
446 bile acid synthesis." Chemistry and Physics of Lipids **204**: 43-56.
- 447 Eyssen, H. (1973). "Role of the gut microflora in metabolism of lipids and sterols." Proceedings
448 of the Nutrition Society **32**(2): 59-63.
- 449 Fiorucci, S. and E. Distrutti (2015). "Bile Acid-Activated Receptors, Intestinal Microbiota, and
450 the Treatment of Metabolic Disorders." Trends in Molecular Medicine **21**(11): 702-714.
- 451 Firl, N., H. Kienberger and M. Rychlik (2014). "Validation of the sensitive and accurate
452 quantitation of the fatty acid distribution in bovine milk." International Dairy Journal **35**(2): 139-
453 144.
- 454 González, I., K.-A. L. Cao, M. J. Davis and S. Déjean (2012). "Visualising associations between
455 paired 'omics' data sets." BioData mining **5**(1): 19-19.

- 456 González, I., S. Déjean, P. G. P. Martin and A. Baccini (2008). "CCA: An R Package to Extend
457 Canonical Correlation Analysis." 2008 **23**(12): 14.
- 458 Grill, J. P., C. Manginot-Dürr, F. Schneider and J. Ballongue (1995). "Bifidobacteria and
459 probiotic effects: Action of Bifidobacterium species on conjugated bile salts." Current
460 Microbiology **31**(1): 23-27.
- 461 Hammons, J. L., W. E. Jordan, R. L. Stewart, J. D. Taulbee and R. W. Berg (1988). "Age and
462 Diet Effects on Fecal Bile Acids in Infants." Journal of Pediatric Gastroenterology and Nutrition
463 **7**(1): 30-38.
- 464 Hascoët, J.-M., M. Chauvin, C. Pierret, S. Skweres, L.-D. Van Egroo, C. Rougé and P. Franck
465 (2019). "Impact of Maternal Nutrition and Perinatal Factors on Breast Milk Composition after
466 Premature Delivery." Nutrients **11**(2): 366.
- 467 Hegele, J., T. Buetler and T. Delatour (2008). "Comparative LC-MS/MS profiling of free and
468 protein-bound early and advanced glycation-induced lysine modifications in dairy products."
469 Analytica Chimica Acta **617**(1): 85-96.
- 470 Henning, C., M. Smuda, M. Girndt, C. Ulrich and M. A. Glomb (2011). "Molecular Basis of
471 Maillard Amide-Advanced Glycation End Product (AGE) Formation in Vivo." Journal of
472 Biological Chemistry **286**(52): 44350-44356.
- 473 Heubi, J. E., W. F. Balistreri and F. J. Suchy (1982). "Bile salt metabolism in the first year of
474 life." The Journal of Laboratory and Clinical Medicine **100**(1): 127-136.
- 475 Hewelt-Belka, W., D. Garwolińska, M. Belka, T. Bączek, J. Namieśnik and A. Kot-Wasik
476 (2019). "A new dilution-enrichment sample preparation strategy for expanded metabolome
477 monitoring of human breast milk that overcomes the simultaneous presence of low- and high-
478 abundance lipid species." Food Chemistry **288**: 154-161.
- 479 Huang, C. T., J. T. Rodriguez, W. E. Woodward and B. L. Nichols (1976). "Comparison of
480 patterns of fecal bile acid and neutral sterol between children and adults." Am J Clin Nutr
481 **29**(11): 1196-1203.
- 482 John, A., R. Sun, L. Maillart, A. Schaefer, E. Hamilton Spence and M. T. Perrin (2019).
483 "Macronutrient variability in human milk from donors to a milk bank: Implications for feeding
484 preterm infants." PLOS ONE **14**(1): e0210610.
- 485 Kim, G.-B., C. M. Miyamoto, E. A. Meighen and B. H. Lee (2004). "Cloning and
486 Characterization of the Bile Salt Hydrolase Genes (*bsh*) from *Bifidobacterium*
487 *bifidum* Strains." Applied and Environmental Microbiology **70**(9): 5603-5612.
- 488 Koletzko, B., S. Baker, G. Cleghorn, U. F. Neto, S. Gopalan, O. Hernell, Q. S. Hock, P.
489 Jirapinyo, B. Lonnerdal, P. Pencharz, H. Pzyrembel, J. Ramirez-Mayans, R. Shamir, D. Turck,
490 Y. Yamashiro and D. Zong-Yi (2005). "Global standard for the composition of infant formula:
491 recommendations of an ESPGHAN coordinated international expert group." J Pediatr
492 Gastroenterol Nutr **41**(5): 584-599.
- 493 Lester, R., J. St Pyrek, J. M. Little and E. W. Adcock (1983). "Diversity of bile acids in the fetus
494 and newborn infant." J Pediatr Gastroenterol Nutr **2**(2): 355-364.
- 495 Lewis, Z. T., S. M. Totten, J. T. Smilowitz, M. Popovic, E. Parker, D. G. Lemay, M. L. Van
496 Tassell, M. J. Miller, Y.-S. Jin, J. B. German, C. B. Lebrilla and D. A. Mills (2015). "Maternal
497 fucosyltransferase 2 status affects the gut bifidobacterial communities of breastfed infants."
498 Microbiome **3**(1): 13.
- 499 Martin, C. R., P.-R. Ling and G. L. Blackburn (2016). "Review of Infant Feeding: Key Features
500 of Breast Milk and Infant Formula." Nutrients **8**(5): 279.

501 McOrist, A. L., R. B. Miller, A. R. Bird, J. B. Keogh, M. Noakes, D. L. Topping and M. A.
502 Conlon (2011). "Fecal Butyrate Levels Vary Widely among Individuals but Are Usually
503 Increased by a Diet High in Resistant Starch." The Journal of Nutrition **141**(5): 883-889.
504 Meng, C., B. Kuster, A. C. Culhane and A. M. Gholami (2014). "A multivariate approach to the
505 integration of multi-omics datasets." BMC Bioinformatics **15**: 162.
506 Meng, C., B. Kuster, A. C. Culhane and A. M. Gholami (2014). "A multivariate approach to the
507 integration of multi-omics datasets." BMC bioinformatics **15**: 162-162.
508 Neelima, R. Sharma, Y. S. Rajput and B. Mann (2013). "Chemical and functional properties of
509 glycomacropeptide (GMP) and its role in the detection of cheese whey adulteration in milk: a
510 review." Dairy science & technology **93**(1): 21-43.
511 Pischetsrieder, M. and T. Henle (2012). "Glycation products in infant formulas: chemical,
512 analytical and physiological aspects." Amino Acids **42**(4): 1111-1118.
513 Poroyko, V., M. Morowitz, T. Bell, A. Ulanov, M. Wang, S. Donovan, N. Bao, S. Gu, L. Hong,
514 J. C. Alverdy, J. Bergelson and D. C. Liu (2011). "Diet creates metabolic niches in the "inmature
515 gut" that shape microbial communities." Nutricion Hospitalaria **26**(6): 1283-1295.
516 Pranger, I. G., E. Corpeleijn, F. A. J. Muskiet, I. P. Kema, C. Singh-Povel and S. J. L. Bakker
517 (2019). "Circulating fatty acids as biomarkers of dairy fat intake: data from the lifelines biobank
518 and cohort study." Biomarkers **24**(4): 360-372.
519 Prentice, A. (1996). "Constituents of Human Milk." Food and Nutrition Bulletin **17**(4): 1-10.
520 Rigo, J., G. Boehm, G. Georgi, J. Jelinek, K. Nyambugabo, G. Sawatzki and F. Studzinski
521 (2001). "An Infant Formula Free of Glycomacropeptide Prevents Hyperthreoninemia in
522 Formula-Fed Preterm Infants." Journal of Pediatric Gastroenterology and Nutrition **32**(2): 127-
523 130.
524 Robinson, S. M. (2015). "Infant nutrition and lifelong health: current perspectives and future
525 challenges." J Dev Orig Health Dis **6**(5): 384-389.
526 Ruan, D. W., Hui; Cheng, Faliang (2018). The Maillard Reaction in Food Chemistry: Current
527 Technology and Applications.
528 Sillner, N., A. Walker, E.-M. Harrieder, P. Schmitt-Kopplin and M. Witting (2019).
529 "Development and application of a HILIC UHPLC-MS method for polar fecal metabolome
530 profiling." Journal of Chromatography B **1109**: 142-148.
531 Sillner, N., A. Walker, D. Hemmler, M. Bazanella, S. S. Heinzmann, D. Haller and P. Schmitt-
532 Kopplin (2019). "Milk-Derived Amadori Products in Feces of Formula-Fed Infants." J Agric
533 Food Chem **67**(28): 8061-8069.
534 Sillner, N., A. Walker, W. Koch, M. Witting and P. Schmitt-Kopplin (2018). "Metformin
535 impacts cecal bile acid profiles in mice." Journal of Chromatography B **1083**: 35-43.
536 Smuda, M., M. Voigt and M. A. Glomb (2010). "Degradation of 1-Deoxy-d-erythro-hexo-2,3-
537 diulose in the Presence of Lysine Leads to Formation of Carboxylic Acid Amides." Journal of
538 Agricultural and Food Chemistry **58**(10): 6458-6464.
539 Sperisen, P., O. Cominetti and F.-P. Martin (2015). "Longitudinal omics modeling and
540 integration in clinical metabonomics research: challenges in childhood metabolic health
541 research." Frontiers in Molecular Biosciences **2**: 44.
542 Tanaka, H., H. Hashiba, J. Kok and I. Mierau (2000). "Bile Salt Hydrolase of Bifidobacterium
543 longum — Biochemical and Genetic Characterization." Applied and Environmental
544 Microbiology **66**(6): 2502-2512.
545 Villaseñor, A., I. Garcia-Perez, A. Garcia, J. M. Posma, M. Fernández-López, A. J. Nicholas, N.
546 Modi, E. Holmes and C. Barbas (2014). "Breast Milk Metabolome Characterization in a Single-

547 Phase Extraction, Multiplatform Analytical Approach." *Analytical Chemistry* **86**(16): 8245-
548 8252.

549 Wandro, S., S. Osborne, C. Enriquez, C. Bixby, A. Arrieta and K. Whiteson (2018). "The
550 Microbiome and Metabolome of Preterm Infant Stool Are Personalized and Not Driven by
551 Health Outcomes, Including Necrotizing Enterocolitis and Late-Onset Sepsis." *mSphere* **3**(3):
552 e00104-00118.

553 Wang, J., Y.-M. Lu, B.-Z. Liu and H.-Y. He (2008). "Electrospray positive ionization tandem
554 mass spectrometry of Amadori compounds." *Journal of Mass Spectrometry* **43**(2): 262-264.

555 WHO (n.d.). "Global Strategy for Infant and Young Child Feeding."


556 Wild, J., M. Shanmuganathan, M. Hayashi, M. Potter and P. Britz-McKibbin (2019).
557 "Metabolomics for improved treatment monitoring of phenylketonuria: urinary biomarkers for
558 non-invasive assessment of dietary adherence and nutritional deficiencies." *Analyst* **144**(22):
559 6595-6608.

560 Wishart, D. S., Y. D. Feunang, A. Marcu, A. C. Guo, K. Liang, R. Vazquez-Fresno, T. Sajed, D.
561 Johnson, C. Li, N. Karu, Z. Sayeeda, E. Lo, N. Assempour, M. Berjanskii, S. Singhal, D. Arndt,
562 Y. Liang, H. Badran, J. Grant, A. Serra-Cayuela, Y. Liu, R. Mandal, V. Neveu, A. Pon, C. Knox,
563 M. Wilson, C. Manach and A. Scalbert (2018). "HMDB 4.0: the human metabolome database for
564 2018." *Nucleic Acids Res* **46**(D1): D608-d617.

565 Zhou, W., M. R. Sailani, K. Contrepolis, Y. Zhou, S. Ahadi, S. R. Leopold, M. J. Zhang, V. Rao,
566 M. Avina, T. Mishra, J. Johnson, B. Lee-McMullen, S. Chen, A. A. Metwally, T. D. B. Tran, H.
567 Nguyen, X. Zhou, B. Albright, B.-Y. Hong, L. Petersen, E. Bautista, B. Hanson, L. Chen, D.
568 Spakowicz, A. Bahmani, D. Salins, B. Leopold, M. Ashland, O. Dagan-Rosenfeld, S. Rego, P.
569 Limcaoco, E. Colbert, C. Allister, D. Perelman, C. Craig, E. Wei, H. Chaib, D. Hornburg, J.
570 Dunn, L. Liang, S. M. S.-F. Rose, K. Kukurba, B. Piening, H. Rost, D. Tse, T. McLaughlin, E.
571 Sodergren, G. M. Weinstock and M. Snyder (2019). "Longitudinal multi-omics of host-microbe
572 dynamics in prediabetes." *Nature* **569**(7758): 663-671.

573


1 **Main**



2

3 **Figure 1.** Multilevel PLS-DA. Scatter plots of (A) RP- and (B) HILIC-UHPLC-MS
 4 measurements (negative electrospray ionization mode). Groups were separated according to
 5 feeding and corrected for time. Numbers represent age of infants at the time of feces sampling
 6 (month 1 – 12, 24). Multilevel PLS-DA loading plots for (C) RP and (D) HILIC UHPLC-MS. Top
 7 15% discriminant features were highlighted for B (breastfed, blue) or both F groups (formula-
 8 fed, brown). The remaining features are presented in grey (NS=not significant). Putative
 9 carbohydrates (open triangle), fatty acids (open inverted triangle) and Maillard products (open
 10 box) are representing significant clusters between B and F groups. Cyprinol-S was
 11 increased in breastfed infants, the Amadori product FruLeulle (*N*-
 12 deoxyfructosylleucylisoleucine) was specifically representing both F groups. *N*-
 13 Acetylgalactosaminitol was increased in the F+ group. *detected as $[M+Cl]^-$ adduct.


14



15

16 **Figure 2.** Diet-related alteration of fatty acid profiles in feces of breastfed (B, blue) and
17 formula-fed infants without (F-, orange) or with probiotics (F+, green) over time. (A) Myristic,
18 (B) arachidonic and (C) eicosapentaenoic acid were increased in group B up to month 7.


19



20

21 **Figure 3.** Relation of six different human milk oligosaccharides (HMOs) in breast milk versus
22 feces. Breast milk samples were categorized in secretor (n = 30) and non-secretor (n = 6).
23 Breast milk and feces samples (n = 31) were mother-child and time matched for comparison.
24 The secretor status determined the relative amount of different HMOs in breast milk as well
25 as in the corresponding feces samples.


26



27

28 **Figure 4.** (A) Fecal excretion profile of the putative Amadori product FruMetAla during the first
29 2 years of life. In formula-fed infants (F-, without probiotics, orange and F+, with probiotics,
30 green) the amount of excreted FruMetAla decreased over time. In breast-fed infants (B, blue)
31 FruMetAla was not detectable. (B) Collision induced dissociation MS/MS experiment (20 eV,
32 positive ionization mode) of FruMetAla in a pooled fecal sample.


33



34

35 **Figure 5.** Profiles of bacterial aromatic amino acid degradation metabolites in feces of
36 breastfed (group B, blue) and formula-fed infants without (group F-, orange) or with probiotics
37 (group F+, green) over time. (A) 4-Hydroxyphenyllactic and (B) indolelactic acid were
38 increased in group B up to month 7. (C) Fecal phenyllactic acid increased over time.

39




40

41 **Figure 6.** Heatmap of all detected bile acids in feces of breastfed (B, blue) and formula-fed
42 infants without (F-, orange) or with probiotics (F+, green) over time. Peak areas (RP-UHPLC-
43 MS) were unit variance scaled. Scaled peak areas > 2 were removed and displayed grey for
44 better visualization. Bile acids which were altered due to the different diets (from multilevel
45 PLS-DA) are marked purple.

46

47

48




49

50

51 **Figure 7.** Regularized canonical correlation analysis (rCCA) was used to investigate the
 52 correlation between two datasets including LC-MS peak area based bile acid data (X) and
 53 OTU data from 16S rRNA sequencing (Y). (A) XY-sample plot is colored according the months
 54 and labeled according to the feeding type.(B) Clustered image map of the cross-correlation
 55 matrix revealed a distinct cluster of positively correlating OTUs with LCA, CDCA and 3-
 56 dehydroCDCA. (C) Corresponding relevance networks for correlations between the two
 57 datasets (XY). OTUs are represented by round and metabolites by rectangular nodes. Edges
 58 are correlation values, derived from rCCA. Correlation strength $> \pm 0.3$ represented by edges
 59 was found for LCA, CDCA and 3-dehydroCDCA. Solely positive correlations were found within
 60 these limits. Most of the correlating OTUs belong to the families *Lachnospiraceae* (green
 61 nodes) and *Ruminococcaceae* (blue nodes), both of them belong to the class of Clostridia.


62

63



64

65 **Figure 8.** Sample spaces of multiple co-inertia analysis to visualize inter- and intra-individual
66 differences over time, shown for the whole fecal polar metabolome screened with HILIC LC-
67 MS approach (A-C) and for short chain fatty acids as selected microbial metabolites (D-F).
68 Each individual (number) is projected within its corresponding feeding group; (A, D) breastfed,
69 (B, E) formula-fed without probiotics and (C, F) formula-fed with probiotics. For the exclusively
70 breastfed group (A) only months 1 – 9 were taken into account because of a reduced number
71 of available samples due to weaning. Samples from the same individual are linked by edges
72 and the shapes represent the different time points. The shorter the edge, the higher the
73 similarity of samples from the same individual. The more similar the metabolic profiles of
74 individuals were the closer the projection in the sample space.



75

76

77 **Figure 9.** Influences of early life nutrition on the fecal metabolome of infants. Dietary
78 ingredients, endogenous compounds but also microbial products are shaping the gut
79 environment of breast- and formula-fed infants. (pBAs = primary bile acids, sBAs = secondary
80 bile acids, BA-SO₄⁻ = bile acid sulfates, AAs = amino acids)

81

1 **Supplementary Information**

2 **Longitudinal profiles of dietary and microbial metabolites in**

3 **formula- and breastfed infants**

4 Nina Sillner et al.


5

6

7


8 Supplementary figures

9



10


11 **Figure S1.** ROC (Receiver Operating Characteristics) curves from the multilevel PLS-DA of
12 (A) HILIC principle component 1, (B) HILIC principle component 2, (C) RP principle component
13 1 and (D) RP principle component 2 UHPLC-MS measurements (negative ionization mode).
14 The area under the curves indicate a very good separation of breastfed (B) versus formula-
15 fed (F- and F+) infants for both data sets in principle component 1 and 2. Less valid differences
16 between F- and F+ were found in component 2.



17

18 **Figure S2.** Collision induced dissociation MS/MS experiments (20 eV, positive ionization
 19 mode) of the putative Amadori product FruAcLys isomers with (A) retention time at 6.2 min
 20 and (B) 6.6 min, measured with HILIC UHPLC-MS, which were found to be significantly
 21 increased in formula-fed infants. (C) Overlaid extracted ion chromatograms of FruAcLys
 22 ($[M+H]^+ = 351.1762 \pm 0.005$ Da) in feces (black) and in a model reaction mixture of L-lysine
 23 with glucose, heated for 1 h at 100 °C in water (blue).


24



25

26 **Figure S3.** Profiles of the aromatic amino acids (A) tyrosine, (B) tryptophan and (C)
 27 phenylalanine in feces of breastfed (group B) and formula-fed infants without (group F-) or
 28 with probiotics (group F+) over time. For tryptophan outliers with peak areas > 300 (n = 5)
 29 were excluded for visualization.

30




31

32 **Figure S4.** Representation of variables defined by the first two canonical variates from a
33 regularized canonical correlation analysis (rCCA) of bile acids and OTU data from 16S rRNA
34 sequencing detected in feces samples from all infants. Bile acids are colored in purple and
35 OTUs in blue.

36


37



38

39 **Figure S5.** Variable spaces of multiple co-inertia analysis to visualize inter- and intra-individual
40 differences over time, separated for feeding groups; (A) breastfed (B), (B) formula-fed without
41 probiotics (F-) and (C) formula-fed with probiotics (F+). Shapes and colors represent the
42 different time points. For group B only months 1 – 9 were taken into account because of a
43 reduced number of available samples in later months due to weaning.


44



45

46 **Figure S6.** Inter- and intra-individual profiles of three selected metabolites. (A) Increased
47 value of taurocholic acid was found in infant 66 (breastfed) at month 7. (B) High amount of
48 hydroxydecanoic acid in infant 71 (F-) at month 9. (C) High signals of cyclamic acid were
49 detected in infant 25 and 102 (both F+) at month 12.

50



51

52 **Figure S7.** Loading plots of multiple co-inertia analysis of six short chain fatty acids (SCFAs)
53 for breastfed (A), F- (B) and F+ (C), illustrating the dispersion of SCFAs over time. Lactic acid
54 showed high inter- and intra-individual variability in all three groups. Butyric and propionic acid
55 were also highly variable in F- and F+ infants.